Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator LaJollaCA, Rhodey Red
Search This Board:
Last Post: 9/16/2014 8:47:24 AM - Followers: 307 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.  Webcast from Cowen Healthcare Conference 03/03/14  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW 
Blog Update from CEO B. Culley 12/12/13  NEW  Data From Proof of Concept Study in Heart Failure 

A service of the U.S. National Institutes of Health


  • Make bi


Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc. Identifier:
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.

Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
Further study details as provided by Mast Therapeutics, Inc.:
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline


Please refer to this study by its identifier: NCT01737814

Contact: Mast Therapeutics Call Center 1-888-965-1238  

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on July 25, 2013





MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.



Exelbine™, or ANX-530 (vinorelbine injectable emulsion), is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). We are seeking a partner or outside investor to continue development of the Exelbine program.


ANX-514 (docetaxel for injectable emulsion) is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel. We are seeking a partner or outside investor to continue development of the ANX-514 program.

2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing

Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14


Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug

Schedule 13D and 13G filings submitted since 03/31/2013

  Filing Company Date of
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 03/31/14 3,000,000 3,000,000
SC 13G SABBY MANAGEMENT, LLC 01/14/2014 4,105,500 3,639,571
SC 13G FRANKLIN RESOURCES INC 07/10/2013 10,987,000 12,000,000
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F     MSTX      
13F     MSTX      




Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries

Investor Relations Contact

Business Development Contact

Careers Contact




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ANX News: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial 06/16/2014 08:00:00 AM
ANX News: Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease 04/14/2014 08:00:00 AM
#12316   Doubt it will get to that, .55 maybe. pray 09/16/14 08:47:23 AM
#12315   This keeps dropping you will be able to kpisme 09/15/14 05:45:02 PM
#12314   Daily cycle .... shorts sell 10,000 first hour pray 09/15/14 12:49:59 PM
#12313   TBD: clearly some varied opinions on this board Rhodey Red 09/11/14 11:50:56 AM
#12312   Thanks Rhodey, just thought I'd drop in and The Bread Man 09/11/14 10:33:10 AM
#12311   Greens days coming sedrik 09/10/14 09:16:48 AM
#12310   Been run so crazy for so long, no pray 09/09/14 11:26:14 AM
#12309   Yes Lady-baron 09/09/14 04:34:06 AM
#12308 Rhodey Red 09/08/14 10:06:09 PM
#12307   Correct me if wrong but is update today pray 09/08/14 09:31:25 AM
#12306   Doubtful. okaly 09/08/14 09:01:58 AM
#12305   Dollar land in the near future imo Guardian 09/08/14 08:43:33 AM
#12304   Mast Therapeutics Announces Positive Top Line Results From harmsen 09/08/14 08:25:01 AM
#12303   Welcome to the MSTX board TBM. Hopefully your Rhodey Red 09/05/14 09:22:19 PM
#12302   Great, we've gone from a vet to a The Bread Man 09/05/14 02:28:11 PM
#12301 Rhodey Red 09/02/14 08:25:55 AM
#12300   Another positive thought regarding New CMO appt.: just Rhodey Red 09/01/14 01:00:07 PM
#12299   Personal Thoughts on New CMO at Mast: Ed Rhodey Red 08/30/14 08:52:00 AM
#12298   Hate to see that, Dr. Vett had been pray 08/29/14 10:45:29 PM
#12297   MSTX news!!! Ecomike 08/29/14 07:10:41 PM
#12296   Good article, wish more investors could see the pray 08/29/14 01:43:22 PM
#12295   Thx for the link Rhodey. Cicant 08/29/14 01:29:26 PM
#12294   Level ii shows a 1.3 million bid at 60... TriggerPuller79 08/29/14 09:31:51 AM
#12293   Recent article from The Life Sciences Report: nothing Rhodey Red 08/28/14 10:48:48 PM
#12292   Lowest volume (under 150,000 traded) in two years. pray 08/28/14 05:12:01 PM
#12291   But no traction. pray 08/27/14 08:06:36 PM
#12290   Nice volume today harmsen 08/27/14 01:51:14 PM
#12289   Short interest info. Rhodey Red 08/27/14 08:59:09 AM
#12288   Seems like the company just cant stay away TriggerPuller79 08/25/14 03:55:53 PM
#12287   Report Results from Phase 2 Study of AIR001 sedrik 08/25/14 08:57:08 AM
#12286   MSTX next week news coming BULLISH sedrik 08/25/14 08:55:25 AM
#12285   BE CAREFUL SHORTS AREA sedrik 08/21/14 09:00:47 AM
#12284   IIRC there was chatter for ages here that Ecomike 08/21/14 05:26:58 AM
#12283   If the volume can stay at a million pray 08/20/14 10:52:54 PM
#12282   In any case, Rhodey's honest enough that he Cicant 08/20/14 02:38:09 PM
#12281   MSTX seems to be creeping higher, early rally Ecomike 08/20/14 02:23:22 PM
#12280   I asked the same about 8 months ago. pray 08/20/14 08:54:36 AM
#12276   Your ridiculous thought processes that dwell on the Rhodey Red 08/16/14 10:22:55 AM
#12274   We do not know if Rhodey in any Cicant 08/16/14 03:03:05 AM
#12272   Indeed we will Cicant!!! All the way to Rhodey Red 08/15/14 08:38:18 PM
#12271   If the first 12-17 months the updates for Cicant 08/15/14 11:11:02 AM
#12270   Yesterday's corporate presentation was excellent. We received a Rhodey Red 08/15/14 09:10:46 AM
#12269  Restored Any thoughts on the presentation? Rhodney? The Sliver Man 08/15/14 12:47:17 AM
#12268   Mast have 4 catalist to end 2014 and sedrik 08/13/14 08:51:07 AM
#12267   Mast Therapeutics To Present At The Canaccord Genuity sedrik 08/13/14 08:49:56 AM
#12266   Up today tomorrow news from conference coming sedrik 08/13/14 08:49:46 AM
#12264   MSTX 4 catalist near 6 month coming sedrik 08/13/14 05:40:35 AM
#12263   Green today, tomorrow news coming from conference sedrik 08/13/14 05:38:37 AM
#12262   Surely this thing has to start moving at The Sliver Man 08/11/14 10:31:14 PM
#12261   Looks positive going forward. One near term TriggerPuller79 08/11/14 08:24:31 PM